{"success":true,"data":{"pressRelease":{"id":"13448","rtpr_id":"nPn9HsBZ2a","ticker":"KALV","exchange":"NASDAQ","all_tickers":["KALV"],"title":"Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders","author":"PR Newswire","published_at":"2026-04-29T16:17:00.035Z","article_body":"Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders\n\nPR Newswire\n\nMILWAUKEE, April 29, 2026\n\nMILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista\n(NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of\nlaw in its recently announced transaction with Chiesi Group.\n\n(https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.html)\n\nClick here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676374-1&h=2922562802&u=https%3A%2F%2Fwww.ademilaw.com%2Fcase%2Fkalvista-pharmaceuticals-inc%2F&a=here)\nto learn how to join our investigation and obtain additional information or\ncontact us at gademi@ademilaw.com (mailto:gademi@ademilaw.com) or toll-free:\n866-264-3995. There is no cost or obligation to you.\n\nKalVista stockholders will receive $27.00 per share in cash, representing\napproximately $1.9 billion in equity value. KalVista insiders will receive\nsubstantial benefits as part of change of control arrangements.\n\nThe transaction agreement unreasonably limits competing transactions for\nKalVista by imposing a significant penalty if KalVista accepts a competing\nbid. We are investigating the conduct of the KalVista board of directors, and\nwhether they are fulfilling their fiduciary duties to all shareholders.\n\nWe specialize in shareholder litigation involving buyouts, mergers, and\nindividual shareholder rights. For more information, please feel free to call\nus. Attorney advertising. Prior results do not guarantee similar outcomes.\n\nContacts\n\nAdemi LLP\nGuri Ademi\nToll Free: (866) 264-3995\nFax: (414) 482-8001\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-kalvista-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302757369.html\n(https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-kalvista-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302757369.html)\n\nSOURCE Ademi LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9HsBZ2a","title":"Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders","author":"PR Newswire","ticker":"KALV","created":"2026-04-29T16:17:00.035Z","tickers":["KALV"],"exchange":"NASDAQ","article_body":"Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders\n\nPR Newswire\n\nMILWAUKEE, April 29, 2026\n\nMILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista\n(NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of\nlaw in its recently announced transaction with Chiesi Group.\n\n(https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.html)\n\nClick here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676374-1&h=2922562802&u=https%3A%2F%2Fwww.ademilaw.com%2Fcase%2Fkalvista-pharmaceuticals-inc%2F&a=here)\nto learn how to join our investigation and obtain additional information or\ncontact us at gademi@ademilaw.com (mailto:gademi@ademilaw.com) or toll-free:\n866-264-3995. There is no cost or obligation to you.\n\nKalVista stockholders will receive $27.00 per share in cash, representing\napproximately $1.9 billion in equity value. KalVista insiders will receive\nsubstantial benefits as part of change of control arrangements.\n\nThe transaction agreement unreasonably limits competing transactions for\nKalVista by imposing a significant penalty if KalVista accepts a competing\nbid. We are investigating the conduct of the KalVista board of directors, and\nwhether they are fulfilling their fiduciary duties to all shareholders.\n\nWe specialize in shareholder litigation involving buyouts, mergers, and\nindividual shareholder rights. For more information, please feel free to call\nus. Attorney advertising. Prior results do not guarantee similar outcomes.\n\nContacts\n\nAdemi LLP\nGuri Ademi\nToll Free: (866) 264-3995\nFax: (414) 482-8001\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-kalvista-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302757369.html\n(https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-kalvista-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302757369.html)\n\nSOURCE Ademi LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-29T16:17:00.071077383Z","server_sent_at_ms":1777479420071},"received_at":"2026-04-29T16:17:00.130Z","source_url":"https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-kalvista-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302757369.html"},"analysis":{"id":"10468","press_release_id":"13448","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["investigation into possible breaches of fiduciary duty","transaction agreement limits competing bids via penalties","insiders receiving substantial benefits in change of control"],"eventType":"legal_litigation","narrative":"Ademi LLP is investigating KalVista Pharmaceuticals' board of directors for potential breaches of fiduciary duty related to the proposed sale to Chiesi Group.\n\nThe investigation focuses on the transaction's terms, under which stockholders would receive $27.00 per share in cash for a total equity value of approximately $1.9 billion.\n\nConcerns include allegations that the deal unreasonably limits competing bids and that KalVista insiders are set to receive substantial change-of-control benefits.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"Legal firm challenges $1.9B Chiesi acquisition, citing deal protection clauses and fiduciary concerns."},"keyFigures":{"dealValueUsd":"$1.9 billion","customDimensions":{"acquisition_price_per_share":"$27.00"}},"quotedText":"The transaction agreement unreasonably limits competing transactions for KalVista by imposing a significant penalty if KalVista accepts a competing bid.","namedEntities":{"people":[{"name":"Guri Ademi","role":"Contact"}],"products":[],"companies":[{"name":"KalVista Pharmaceuticals Inc.","ticker":"KALV"},{"name":"Chiesi Group","relationship":"acquirer"},{"name":"Ademi LLP","relationship":"legal counsel"}],"dollarAmounts":[{"amount":"$27.00","context":"per share cash consideration"},{"amount":"$1.9 billion","context":"total equity value"}]},"materialImpact":{"score":4,"reasoning":"While the primary event is a law firm investigation (typically low impact), the underlying context is a $1.9 billion acquisition of the company. The investigation alleges significant issues (fiduciary breaches, deal protection) that could affect the transaction process, warranting a higher score."},"tickerRelevance":{"others":[],"primary":"KALV"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["m_and_a"],"importanceComponents":{"sourceType":"Third-party legal alert","tickerTier":"small-mid-cap","eventGravity":"M&A context ($1.9B)","sectorWeight":"Biotech"}},"event_type":"legal_litigation","event_type_secondary":["m_and_a"],"sentiment":"neutral","material_impact_score":4,"narrative":"Ademi LLP is investigating KalVista Pharmaceuticals' board of directors for potential breaches of fiduciary duty related to the proposed sale to Chiesi Group.\n\nThe investigation focuses on the transaction's terms, under which stockholders would receive $27.00 per share in cash for a total equity value of approximately $1.9 billion.\n\nConcerns include allegations that the deal unreasonably limits competing bids and that KalVista insiders are set to receive substantial change-of-control benefits.","key_figures":{"dealValueUsd":"$1.9 billion","customDimensions":{"acquisition_price_per_share":"$27.00"}},"named_entities":{"people":[{"name":"Guri Ademi","role":"Contact"}],"products":[],"companies":[{"name":"KalVista Pharmaceuticals Inc.","ticker":"KALV"},{"name":"Chiesi Group","relationship":"acquirer"},{"name":"Ademi LLP","relationship":"legal counsel"}],"dollarAmounts":[{"amount":"$27.00","context":"per share cash consideration"},{"amount":"$1.9 billion","context":"total equity value"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-29T20:57:52.226Z","global_importance":35,"audience_relevance":25,"importance_components":{"sourceType":"Third-party legal alert","tickerTier":"small-mid-cap","eventGravity":"M&A context ($1.9B)","sectorWeight":"Biotech"}},"durationMs":91899,"modelName":"glm-4.7"}}